Trials / Terminated
TerminatedNCT02791191
A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 316 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3202626 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2016-06-16
- Primary completion
- 2018-07-02
- Completion
- 2018-07-02
- First posted
- 2016-06-06
- Last updated
- 2021-04-19
- Results posted
- 2021-04-19
Locations
76 sites across 4 countries: United States, Australia, Canada, Japan
Source: ClinicalTrials.gov record NCT02791191. Inclusion in this directory is not an endorsement.